Authors
Haifa E Alfassam, Emadeldin M Kamel, Sarah I Othman, Hanan M Alharbi, Hassan A Rudayni, Ahmed A Allam, Al Mokhtar Lamsabhi
Published in
Chemical biology & drug design. Volume 108. Issue 4. Pages e70415.
Abstract
The interaction between c-Myb and the CBP/p300 KIX domain is a key transcriptional event in acute myeloid leukemia (AML) and represents an attractive target for small-molecule intervention. In this study, we applied an integrated computational-experimental strategy to identify new N-aryl anthranilic acid disruptors of the c-Myb-KIX protein-protein interaction. A scaffold-focused library of 3656 N-aryl anthranilic acid derivatives was filtered, docked to the c-Myb-binding groove of KIX (PDB 2AGH), and the top hits were further evaluated by MD simulations, MM/PBSA, FEL, and ADMET analyses. This workflow prioritized four hits (C1-C4) for experimental testing. Computational analyses showed that all four compounds remained bound within the α1/α3 Myb-facing groove, but differed markedly in their predicted effects on the c-Myb-KIX interface. Among them, C3 emerged as the strongest predicted disruptor, whereas C1 was predicted to stabilize the complex. The analysis further showed that C3 produced the largest destabilizing effect on the c-Myb-KIX interface (+4.57 kcal/mol), followed by C2 (+2.30 kcal/mol) and C4 (+1.40 kcal/mol), whereas C1 stabilized the complex (-6.47 kcal/mol). These predictions were validated by microscale thermophoresis (MST). The binary c-Myb-KIX interaction showed an apparent Kd of 26.71 ± 0.54 μM, and the compounds inhibited complex formation with IC50 values of 99.6 ± 20.5 μM (C1), 54.7 ± 22.1 μM (C2), 16.5 ± 0.8 μM (C3), and 27.2 ± 2.7 μM (C4). Notably, C3 outperformed the reference inhibitor Naphthol AS-E phosphate (28.8 ± 3.1 μM). Overall, these findings identify C3 as a promising lead and establish N-aryl anthranilic acids as a tractable scaffold for targeting the c-Myb-CBP/p300 KIX interaction.
PMID:
42844726
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0